background
bacteri
coinfect
import
contributor
morbid
mortal
influenza
pandem
investig
incid
risk
factor
outcom
patient
influenza
pneumonia
bacteri
coinfect
method
prospect
observ
studi
consecut
hospit
patient
influenza
viru
communityacquir
pneumonia
cap
compar
case
without
bacteri
coinfect
result
incid
influenza
infect
cap
pandem
period
n
studi
patient
bacteri
coinfect
frequent
isol
bacteri
pathogen
streptococcu
pneumonia
pseudomona
aeruginosa
predictor
bacteri
coinfect
chronic
obstruct
pulmonari
diseas
copd
increas
platelet
count
hospit
mortal
factor
associ
mortal
age
year
presenc
septic
shock
need
mechan
ventil
although
patient
bacteri
coinfect
present
higher
pneumonia
journal
infect
sever
index
risk
class
hospit
mortal
similar
patient
without
bacteri
coinfect
vs
respect
p
z
conclus
bacteri
coinfect
frequent
influenza
pneumonia
copd
increas
platelet
count
main
predictor
although
associ
higher
sever
scale
admiss
bacteri
coinfect
influenc
mortal
patient
influenza
viru
infect
import
caus
morbid
mortal
sever
patient
infect
novel
swineorigin
influenza
viru
north
america
world
health
organ
declar
influenza
pandem
caus
novel
soiv
june
decemb
countri
report
case
death
regist
august
announc
pandem
move
postpandem
period
report
total
confirm
death
worldwid
season
pandem
influenza
frequent
complic
bacteri
infect
bacteri
coinfect
found
around
case
season
influenza
pathogen
often
report
includ
haemophilu
influenza
staphylococcu
aureu
streptococcu
pneumonia
bacteri
coinfect
import
contributor
morbid
mortal
bacteri
pneumonia
complic
influenza
infect
major
caus
death
influenza
pandem
period
season
influenza
activ
interpandem
period
bacteri
coinfect
frequent
report
fatal
case
influenza
pandem
pneumonia
frequent
pathogen
identifi
report
specif
popul
criticallyil
patient
found
bacteri
coinfect
rang
patient
influenza
viru
pneumonia
howev
incid
role
bacteri
coinfect
outcom
patient
influenza
virusassoci
pneumonia
well
describ
gener
popul
therefor
determin
incid
risk
factor
outcom
patient
influenza
virusassoci
communityacquir
pneumonia
bacteri
coinfect
prospect
observ
studi
consecut
adult
patient
hospit
diagnosi
influenza
communityacquir
pneumonia
cap
patient
enrol
spanish
center
hospit
clinic
barcelona
hospit
la
fe
valencia
follow
inform
record
demograph
data
comorbid
time
ill
onset
hospit
admiss
previou
antibiot
corticosteroid
therapi
influenza
pneumococc
vaccin
microbiolog
chest
radiolog
laboratori
find
complic
determin
sever
ill
pneumonia
sever
index
psi
calcul
patient
within
h
admiss
exclud
patient
immunosuppress
eg
patient
neutropenia
chemotherapi
bone
marrow
transplant
patient
druginduc
immunosuppress
result
solidorgan
transplant
corticosteroid
cytotox
therapi
patient
hivrel
disord
health
care
associ
pneumonia
hcap
patient
studi
approv
ethic
committe
center
regist
patient
identif
remain
anonym
inform
consent
waiv
due
observ
natur
studi
fact
activ
emerg
public
health
respons
protocol
sampl
perform
patient
diagnosi
cap
hospit
admiss
two
institut
sampl
consid
valid
microbiolog
assess
includ
sputum
cultur
two
set
blood
cultur
urin
antigen
pneumonia
legionella
pneumophila
appli
patient
detect
pneumonia
antigen
urin
perform
rapid
immunochromatograph
assay
nowtm
binax
portland
usa
detect
l
pneumophila
serogroup
antigen
urin
perform
immunoenzymat
comerci
method
legionella
urinari
antigen
binax
addit
diagnost
sampl
techniqu
occasion
use
pleural
punctur
tracheobronchi
aspir
predefin
threshold
cfuml
bronchoscopi
quantit
cultur
bronchoalveolar
lavag
predefin
threshold
cfuml
sputum
blood
sampl
obtain
bacteri
cultur
start
antibiot
therapi
emerg
depart
urin
sampl
pneumonia
l
pneumophila
antigen
detect
obtain
within
h
hospit
admiss
valid
sputum
sampl
criteria
purul
sampl
polymorphonuclear
leukocyt
per
high
power
microscop
field
squamou
epitheli
cell
per
high
power
microscop
field
blood
sampl
serolog
atyp
pathogen
perform
admiss
within
third
sixth
week
thereaft
possibl
protocol
diagnosi
two
institut
patient
admit
hospit
period
diagnosi
cap
test
influenza
institut
nasopharyngealswab
specimen
collect
admiss
viral
diagnosi
perform
rna
nasopharyngealswab
swab
microbiolog
servic
particip
hospit
revers
transcriptionpolymeras
chain
reaction
rtpcr
base
method
use
reagent
provid
free
charg
center
diseas
control
cdc
atlanta
ga
usa
test
perform
accord
publish
guidelin
cdc
addit
nasopharyngealswab
specimen
patient
test
use
multiplex
pcr
use
rvp
fast
assay
luminexeabbott
molecular
wiesbaden
germani
accord
manufactur
instruct
qualit
detect
influenza
viru
b
respiratori
syncyti
viru
human
coronaviru
strain
parainfluenza
type
human
metapneumoviru
rhinovirusenteroviru
adenoviru
human
bocaviru
diagnosi
atyp
pneumonia
base
follow
test
fourfold
increas
igg
level
mycoplasma
pneumonia
chlamidophila
pneumonia
l
pneumophila
coxiella
burnetii
singl
increas
igm
titer
pneumonia
c
pneumonia
c
burnetii
igg
evalu
complement
fixat
diess
l
pneumophila
c
burnetti
c
pneumonia
pneumonia
igm
c
pneumonia
pneumonia
evalu
enzym
immunoassay
elisa
vircel
virotec
respect
definit
cap
base
current
infecti
diseas
societi
america
idsa
american
thorac
societi
at
guidelin
sever
cap
defin
presenc
either
one
two
major
criteria
least
three
nine
minor
criteria
fever
defin
two
consecut
measur
c
regist
presenc
septic
shock
acut
respiratori
distress
syndrom
ard
criteria
confirm
case
defin
patient
diagnosi
pneumonia
laboratoryconfirm
pandem
influenza
viru
infect
rtpcr
confirm
case
includ
current
studi
bacteri
coinfect
diagnos
patient
one
posit
cultur
obtain
blood
normal
steril
fluid
valid
sputum
bronchoscop
sampl
andor
posit
urinari
antigen
pneumonia
l
pneumophila
time
hospit
admiss
categor
variabl
describ
frequenc
percentag
continu
variabl
describ
mean
standard
deviat
sd
median
interquartil
rang
iqr
data
normal
distribut
kolmogorovesmirnov
test
categor
variabl
compar
chisquar
test
fisher
exact
test
appropri
continu
variabl
compar
use
student
ttest
normal
demonstr
otherwis
nonparametr
mannewhitney
u
test
perform
univari
multivari
logist
regress
analys
perform
identifi
variabl
predict
patient
bacteri
coinfect
depend
variabl
variabl
analyz
age
gender
bodi
mass
index
bmi
smoke
alcohol
consumpt
previou
antibiot
influenza
vaccin
pneumococc
vaccin
chronic
obstruct
pulmonari
diseas
copd
chronic
cardiovascular
diseas
diabet
mellitu
neurolog
diseas
chronic
renal
diseas
chronic
liver
diseas
pneumonia
sever
index
psi
risk
class
serum
creatinin
serum
creatinin
kinas
serum
lactat
dehydrogenas
creactiv
protein
leukocyt
platelet
mechan
ventil
septic
shock
multilobar
infiltr
univari
multivari
logist
regress
analys
perform
predict
mortal
depend
variabl
independ
variabl
analyz
mention
plu
fio
mechan
ventil
bacteri
coinfect
bacteremia
ard
criteria
variabl
show
signific
result
univari
p
includ
multivari
logist
regress
backward
stepwis
model
determin
independ
relat
prognosi
hosmerelemeshow
goodnessoffit
test
perform
assess
overal
fit
model
predict
capac
bacteri
coinfect
continu
variabl
assess
receiv
oper
characterist
roc
curv
area
curv
auc
optim
cutoff
valu
sensit
specif
predict
posit
valu
predict
neg
valu
posit
likelihood
ratio
neg
likelihood
ratio
calcul
test
twotail
signific
set
analys
perform
spss
version
window
spss
inc
chicago
illinoi
usa
studi
period
consecut
patient
admit
cap
hospit
barcelona
valencia
regist
among
patient
influenza
pneumonia
barcelona
valencia
mean
age
ae
year
rang
patient
older
year
fiftyon
patient
comorbid
patient
obes
bmi
patient
morbidli
obes
bmi
five
patient
pregnant
women
main
demograph
clinic
characterist
patient
detail
tabl
median
iqr
time
onset
symptom
hospit
day
frequent
symptom
sign
hospit
admiss
cough
fever
dyspnea
arthromyalgia
chill
gastrointestin
manifest
pleural
pain
rhinorrhea
thirtythre
patient
receiv
previou
antibiot
treatment
admiss
vast
major
patient
classifi
low
risk
accord
psi
risk
class
overal
patient
bacteri
coinfect
bacteri
pathogen
identifi
summar
tabl
four
patient
bacteri
coinfect
bacteremia
pneumonia
case
fusobacterium
sp
patient
bacteri
coinfect
frequent
copd
higher
psi
risk
class
leukocyt
platelet
count
longer
length
hospit
stay
nonsignific
trend
higher
serum
level
creactiv
protein
frequent
need
mechan
ventil
howev
need
icu
admiss
rate
septic
shock
hospit
mortal
similar
among
patient
without
bacteri
coinfect
tabl
statist
signific
variabl
univari
analysi
report
tabl
multivari
analysi
independ
predictor
bacteri
coinfect
underli
copd
increas
platelet
count
admiss
model
well
calibr
pvalu
hosmerelemeshow
test
use
roc
analysi
optim
cutpoint
bacteri
coinfect
per
mm
auc
sensit
specif
predict
posit
valu
predict
neg
valu
posit
likelihood
ratio
neg
likelihood
ratio
antibiot
regimen
fluoroquinolon
monotherapi
betalactam
plu
macrolid
fluoroquinolon
plu
betalactam
betalactam
monotherapi
combin
patient
receiv
oseltamivir
dose
mg
bid
mg
bid
day
twentyseven
patient
receiv
prior
steroid
admiss
empir
antibiot
treatment
inappropri
case
bacteri
coinfect
one
patient
inappropri
treatment
die
pathogen
frequent
associ
inadequ
treatment
p
aeruginosa
case
pneumonia
fusobacterium
case
twelv
patient
die
hospit
case
icu
characterist
survivor
nonsurvivor
detail
tabl
bacteri
coinfect
similarli
frequent
nonsurvivor
survivor
sever
variabl
significantli
associ
death
univari
analysi
tabl
multivari
bacteri
coinfect
frequent
patient
hospit
influenza
pneumonia
relev
predictor
bacteri
coinfect
underli
copd
higher
platelet
count
admiss
although
associ
higher
psi
risk
class
bacteri
coinfect
relat
increas
mortal
patient
first
investig
report
consecut
patient
admit
influenza
pneumonia
whole
pandem
period
two
spanish
hospit
experi
studi
respiratori
infect
unlik
previou
trial
includ
critic
noncrit
ill
patient
patient
admit
hospit
cap
period
underw
systemat
microbi
investig
includ
detect
test
influenza
viru
bacteri
pathogen
interestingli
hospit
found
case
hospit
pneumonia
pandem
period
present
influenza
infect
rate
bacteri
coinfect
seri
slightli
higher
report
patient
season
influenzaassoci
cap
criticallyil
icu
patient
influenza
pandem
report
fatal
case
influenza
shown
great
variabl
rate
bacteri
pathogen
detect
autopsi
rang
rate
bacteri
coinfect
seri
could
possibl
underestim
sinc
patient
receiv
previou
antibiot
thu
limit
chanc
detect
bacteri
coinfect
thu
true
bacteri
coinfect
rate
might
even
higher
inde
studi
use
molecular
techniqu
masstag
pcr
test
microbi
agent
nasopharyng
swab
found
rate
bacteri
pathogen
sampl
patient
influenza
pneumonia
frequent
bacteri
pathogen
seri
accord
recent
studi
evalu
season
novel
influenza
pneumonia
unexpectedli
p
aeruginosa
second
frequent
bacteri
pathogen
wherea
aureu
rare
found
identifi
h
influenza
presenc
p
aeruginosa
may
relat
high
proport
patient
sever
cap
copd
bacteri
coinfect
group
absenc
h
influenza
patient
also
unusu
pathogen
abbrevi
odd
ratio
ci
confid
interv
na
avail
mgdl
indic
increas
one
mgdl
unit
indic
increas
ten
unit
frequent
bacteri
pathogen
identifi
patient
influenza
argentina
howev
molecular
techniqu
pcr
use
studi
well
known
improv
diagnosi
etiolog
cap
despit
recent
report
three
case
pneumonia
cmrsa
find
case
mrsa
seri
regard
aureu
frequent
bacteri
pathogen
identifi
much
select
popul
sever
immunosuppress
patient
solid
organ
transplant
substanti
differ
present
studi
first
studi
assess
predictor
bacteri
coinfect
influenza
pneumonia
multivari
analysi
underli
copd
increas
platelet
count
independ
predict
presenc
bacteri
coinfect
seri
previou
tracheobronchi
colon
frequent
copd
patient
bacteri
pathogen
pneumonia
p
aeruginosa
frequent
report
copd
exacerb
bacteri
etiolog
may
explain
presenc
bacteria
frequent
bacteri
isol
patient
thrombocytosi
well
thrombocytopenia
recent
describ
independ
predictor
death
cap
platelet
inflammatori
cell
import
role
antimicrobi
host
defens
henc
appear
marker
bacteri
infect
patient
cap
studi
higher
level
creactiv
protein
admiss
nearli
significantli
higher
patient
bacteri
coinfect
although
measur
procalcitonin
recent
studi
show
procalcitonin
creactiv
protein
may
potenti
assist
discrimin
sever
lower
respiratori
tract
infect
bacteri
influenza
origin
due
increas
evid
use
biomark
diagnosi
manag
cap
role
biomark
discrimin
patient
influenza
without
bacteri
coinfect
need
prospect
investig
overal
hospit
mortal
influenza
pneumonia
popul
slightli
higher
expect
patient
cap
gener
season
influenzaassoci
pneumonia
although
patient
rel
young
averag
age
year
togeth
major
sever
criteria
septic
shock
need
invas
ventil
independ
predictor
mortal
observ
previou
studi
data
support
specif
impact
bacteri
coinfect
outcom
influenza
pneumonia
despit
fact
bacteri
coinfect
associ
higher
psi
risk
class
admiss
trend
wors
renal
function
need
mechan
ventil
howev
current
sever
score
psi
limit
valu
influenza
pneumonia
sinc
underestim
mortal
rate
like
due
averag
age
patient
recent
report
two
import
strength
studi
patient
includ
consecut
avoid
way
potenti
bia
use
systemat
microbiolog
diagnost
protocol
two
center
sever
limit
need
address
first
bacteri
coinfect
might
underestim
case
receiv
previous
antibiot
second
rel
low
number
death
possibl
due
favor
influenc
administr
oseltamivir
patient
may
limit
identif
factor
potenti
relat
death
conclus
data
indic
bacteri
coinfect
frequent
influenza
pneumonia
copd
increas
platelet
count
main
predictor
although
associ
higher
sever
scale
admiss
bacteri
coinfect
influenc
mortal
patient
abbrevi
z
odd
ratio
ci
z
confid
interv
ldh
z
lactat
dehydrogenas
psi
z
pneumonia
sever
index
ard
z
acut
respiratori
distress
syndrom
mgdl
indic
increas
one
mgdl
ul
indic
increas
one
hundr
ul
